| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PSC.2005.05.004 |
| P698 | PubMed publication ID | 16122570 |
| P50 | author | Philip D. Harvey | Q52561006 |
| P2093 | author name string | Christopher R Bowie | |
| P433 | issue | 3 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 613-33, 626 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Psychiatric Clinics of North America | Q7256223 |
| P1476 | title | Cognition in schizophrenia: impairments, determinants, and functional importance | |
| P478 | volume | 28 |
| Q40363119 | A Serious Game to Improve Cognitive Functions in Schizophrenia: A Pilot Study |
| Q41117908 | A commentary on "Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders". |
| Q34322964 | A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. |
| Q37272791 | A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia |
| Q36883313 | A review of the effects of modafinil on cognition in schizophrenia |
| Q62687362 | A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses |
| Q37243714 | Absence of established sex differences in patients with schizophrenia on a two-dimensional object array task |
| Q55617842 | Age at Onset and Social Cognitive Impairment in Clinically Stabilized Patients with Schizophrenia: An Ecological Cross-Sectional Study. |
| Q36243977 | Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies |
| Q52673198 | Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition. |
| Q48274723 | Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders |
| Q50305927 | Asperger Syndrome and Schizophrenia: A Comparative Neuropsychological Study |
| Q51030720 | Assessing functional performance using computer-based simulations of everyday activities. |
| Q50439837 | Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment |
| Q24198212 | Atomoxetine for schizophrenia |
| Q37867702 | Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions |
| Q40610600 | Cognitive aspects of schizophrenia |
| Q26864324 | Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches |
| Q43484862 | Cognitive functioning and negative symptoms in first episode schizophrenia: different patterns of correlates |
| Q34082617 | Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia |
| Q88536296 | Cognitive remediation in large systems of psychiatric care |
| Q46497361 | Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q38813710 | Conflict adaptation in schizophrenia: reviewing past and previewing future efforts |
| Q34252367 | Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum |
| Q40102289 | Conversation-based assessment of social cognition in adults with traumatic brain injury |
| Q21129280 | Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption |
| Q35750348 | Deficits in cue detection and intention retrieval underlie prospective memory impairment in schizophrenia |
| Q34805258 | Diabetes and cognitive deficits in chronic schizophrenia: a case-control study |
| Q36857761 | Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms |
| Q50782411 | Diagnostic accuracy of a new instrument for detecting cognitive dysfunction. |
| Q34574484 | Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice |
| Q34443241 | Discrimination within Recognition Memory in Schizophrenia. |
| Q37149873 | Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia |
| Q64258877 | Distinct Time-Course of Alterations of Groups I and II Metabotropic Glutamate Receptor and GABAergic Receptor Expression Along the Dorsoventral Hippocampal Axis in an Animal Model of Psychosis |
| Q37335111 | Distinct conflict resolution deficits related to different facets of Schizophrenia |
| Q33854087 | Distinct multivariate brain morphological patterns and their added predictive value with cognitive and polygenic risk scores in mental disorders |
| Q34615831 | Distress intolerance and clinical functioning in persons with schizophrenia |
| Q51168622 | Ecological assessments of activities of daily living and personal experiences with Mobus, an assistive technology for cognition: a pilot study in schizophrenia. |
| Q37681434 | Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial |
| Q41875383 | Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses |
| Q38388680 | Emotion word use in the conversational speech of schizophrenia patients. |
| Q50302630 | Gestalt perception and local-global processing in high-functioning autism |
| Q24649621 | Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia |
| Q46015345 | Impaired verbal learning in forensic inpatients with Schizophrenia Spectrum Disorder. |
| Q55290817 | Implementing cognitive remediation and social cognitive interaction training into standard psychosis care. |
| Q48118197 | Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity |
| Q99594586 | In silico hippocampal modeling for multi-target pharmacotherapy in schizophrenia |
| Q38499006 | Language in Schizophrenia Part 1: An Introduction |
| Q36521858 | Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities |
| Q34336202 | Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia |
| Q30491310 | Molecular targets for treating cognitive dysfunction in schizophrenia. |
| Q36335360 | Mortality in Schizophrenia and Other Psychoses: Data from the South Korea National Health Insurance Cohort, 2002-2013. |
| Q34086286 | Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy |
| Q48061884 | Neurocognition, functional competence and self-reported functional impairment in psychometrically defined schizotypy |
| Q45327961 | Neurocognitive function in schizophrenia with comorbid posttraumatic stress disorder |
| Q36091817 | Neuropsychological functioning in bipolar disorder and schizophrenia |
| Q33856940 | Neuropsychological models of autism spectrum disorders - behavioral evidence and functional imaging |
| Q47156248 | Neuropsychological performance as endophenotypes in extended schizophrenia families from the Central Valley of Costa Rica |
| Q48526140 | Performance on the Cognitive Estimation Test in schizophrenia |
| Q34096784 | Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum |
| Q36401912 | Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs |
| Q42367850 | Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia |
| Q36564979 | Pharmacological approaches to the management of cognitive dysfunction in schizophrenia |
| Q41910174 | Prospective memory impairments in schizophrenic patients |
| Q24643462 | Recent advances in social skills training for schizophrenia |
| Q39972149 | Recovery from schizophrenia: a four-year study of an inner city cohort |
| Q34550685 | Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study |
| Q33678615 | Resting state and task-induced deactivation: A methodological comparison in patients with schizophrenia and healthy controls |
| Q36756401 | Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder |
| Q36791070 | Self-assessment of functional status in schizophrenia |
| Q33946959 | Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness |
| Q34845907 | Social cognition in adolescent girls with fragile x syndrome |
| Q45364521 | Spatial behavior reflects the mental disorder in OCD patients with and without comorbid schizophrenia |
| Q28545094 | The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis |
| Q36325461 | The Relationship between Language Ability and Cognitive Function in Patients with Schizophrenia |
| Q35237288 | The assessment of neuropsychological functioning in schizophrenia |
| Q34224064 | The course of vocational functioning in patients with schizophrenia: Re-examining social drift |
| Q35096578 | The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan. |
| Q42791247 | The importance of measuring psychosocial functioning in schizophrenia. |
| Q36898681 | The pipeline and future of drug development in schizophrenia. |
| Q40188554 | The quest for developing new treatments from imaging techniques: promises, problems and future potential |
| Q34531316 | The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study |
| Q30493072 | Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. |
| Q42121970 | Validation of a Computerized test of Functional Capacity |
| Q46685755 | Where are patients who have co-occurring mental and physical diseases located? |
| Q34581055 | Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. |
Search more.